1. Home
  2. PLBC vs EDIT Comparison

PLBC vs EDIT Comparison

Compare PLBC & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plumas Bancorp

PLBC

Plumas Bancorp

HOLD

Current Price

$57.23

Market Cap

363.9M

Sector

Finance

ML Signal

HOLD

Logo Editas Medicine Inc.

EDIT

Editas Medicine Inc.

HOLD

Current Price

$2.76

Market Cap

432.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBC
EDIT
Founded
1980
2013
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
363.9M
432.8M
IPO Year
2002
2016

Fundamental Metrics

Financial Performance
Metric
PLBC
EDIT
Price
$57.23
$2.76
Analyst Decision
Buy
Strong Buy
Analyst Count
3
5
Target Price
$57.67
$5.30
AVG Volume (30 Days)
64.2K
3.7M
Earning Date
04-15-2026
05-11-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
37.50
EPS
1.38
N/A
Revenue
N/A
$31,937,000.00
Revenue This Year
$25.59
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
$40.43
N/A
Revenue Growth
N/A
132.64
52 Week Low
$39.70
$1.66
52 Week High
$57.51
$4.54

Technical Indicators

Market Signals
Indicator
PLBC
EDIT
Relative Strength Index (RSI) 68.07 50.25
Support Level $50.86 $2.47
Resistance Level $57.51 $3.27
Average True Range (ATR) 1.71 0.22
MACD 0.12 0.01
Stochastic Oscillator 96.30 52.56

Price Performance

Historical Comparison
PLBC
EDIT

About PLBC Plumas Bancorp

Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.

About EDIT Editas Medicine Inc.

Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary gene editing platform based on CRISPR technology and continues to expand its capabilities. CRISPR uses a protein-RNA complex composed of an enzyme, including either Cas9 (CRISPR-associated protein 9) or Cas12a (CRISPR from Prevotella and Francisella 1, also known as Cpf1). The company has a single operating segment, which is the business of developing and commercializing gene editing technology.

Share on Social Networks: